- ProBio appoints Allen Guo as CEO, Whitney Winters as SVP of U.S. Business Development, and Michael Vreeland as U.S. Site Head and Interim Head of Process Development.
ProBio, a global contract development and manufacturing organisation (CDMO), has announced a strategic leadership reshuffle effective 1 December 2024. Allen Guo will serve as Chief Executive Officer, Whitney Winters as Senior Vice President of U.S. Business Development, and Michael Vreeland as U.S. Site Head and Interim Head of Process Development. The appointments are expected to bolster the company’s efforts in delivering customised solutions for biologics and advanced therapies.
The new CEO, Allen Guo, brings 16 years of experience at notable organisations, including Janssen and Lonza. Since joining ProBio in 2021, he has led business development efforts critical to the company’s revenue growth. Commenting on his appointment, Guo stated: “Together with our talented team, I am committed to driving innovation, delivering quality solutions, and empowering our customers to develop therapies that make a lasting impact on patients’ lives.”
Whitney Winters, who joined ProBio earlier this year, will now oversee U.S. business development and marketing. With 17 years of experience in sales and strategy, including at West Pharmaceutical Services, she aims to expand ProBio’s presence in the U.S. market. Winters expressed enthusiasm for her new role, emphasising the company’s “cutting-edge CDMO capabilities” and its potential to collaborate with customers on transformative therapies.
Michael Vreeland steps in as U.S. Site Head, overseeing operations at ProBio’s Hopewell, New Jersey facility, which specialises in plasmid DNA and viral vector production. Vreeland’s background includes leadership roles at Curia and Thermo Fisher Scientific, bringing deep expertise in cGMP manufacturing and process development.
Founded in 2020, ProBio has supported over 108 Investigational New Drug (IND) clearances globally. Its board chairman, Li Zhu, remarked that the newly appointed leaders are “uniquely qualified” to guide the company’s next phase of growth. Former CEO Dr. Li Chen will stay on as a consultant to ensure a seamless transition.
Overview of outsourcing trends 
